Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Week in Review: GenScript and its Legend Bio Subsidiary Raise $1 Billion from Hillhouse

Deals and Financings   GenScript raised more than $1 billion from Hillhouse Capital in various investments including $500 million for GenScript's Legend CAR-T subsidiary; Elpiscience Biopharma, a  Shanghai  cancer immunotherapy company, closed a $105 million Series C round to start US trials of its innovative portfolio. Beijing Hygea Medical Technology completed a $77 million Series C financing for its medical devices, including a minimally invasive ablation device for cancer; Alebund Pharma, a  Shanghai  company developing renal disease therapies, raised $60 million in a Series B round led by Quan Capital; Kinnate, a San Diego biopharma. closed a $35 million Series A financing to form a China JV to develop its own oncology drugs in Greater China; Fulgent Genetics of Los Angeles made a $19 million investment in its China JV, FF Gene Biotech, to gain majority control of the testing company; Shenzhen Pregene Bio out-licensed Indian rights for its anti-BCMA CAR-T cell therapy to Dr. Reddy's Labs for $5 million in upfront and milestone payments; Viva Bio, a  Shanghai  drug discovery CRO, announced a strategic collaboration with  Beijing 's BioMap, an AI + biological computing services company;    Trials and Approvals   Shanghai Reistone Biopharma started a global Phase III clinical trial of its JAK1 inhibitor in patients with atopic dermatitis; Antengene of Shanghai announced  China  approved a Phase III trial of selinexor to treat endometrial cancer; Connect Biopharma, a Taicang-San Diego company, dosed the first patient in a global Phase II trial of a treatment for persistent asthma;  COVID-19 Pandemic   Shanghai Fosun Pharma formed a $200 million JV with its COVID-19 partner BioNTech to manufacture their partnered mRNA vaccine in  China ; Company News   LianBio, a Shanghai-Princeton biotech, hired Yizhe Wang, PhD, to be the company's CEO and Board of Directors member; San Diego 's aTyr and its  Hong Kong  subsidiary, Pangu, are developing bi-specific antibodies to treat diseases with Neuropilin-2 (NRP2) overexpression.  Stock Symbols: (HK: 1548) (NSDQ: LEGN) (NSDQ: KNTE) (NSDQ: FLGT) (BSE: 500124) (HK: 1873) (HK: 6996) (NSDQ: CNTB) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.